HKEX: 3347 - Hangzhou Tigermed Consulting Co., Ltd

Yield per half year: +4.96%
Sector: Healthcare

Hangzhou Tigermed Consulting Co., Ltd

Underestimation

Parameter Grade Value Sector average Difference with sector, % Average for 5 years Difference from average, %
P/E
8/10
12.89 35.42 -63.6% 38.88 -66.84%
P/S 3.53 7.59 -53.42%
P/BV 1.07 3.68 -71.04%
P/FCF 73.77 55.3 33.4%
Ev/Ebitda 21.43 2.91 636.96%
Ev/S 7.68 23.72 -67.6%
Ev/FCF 67.8 63.78 6.31%
E/P 0.0328 0.0326 0.5188%

Efficiency

Parameter Grade Value Sector average Difference with sector, % Average for 5 years Difference from average, %
Ebitda margin
10/10
41.4 -11.9 -447.85% 52.71 -21.46%
ROE 9.96 5.19 92.06%
ROA 7.09 3.47 104.32%
ROIC 0 0 0%
ROS 27.42 -11.49 -338.71%
ROCE 0 6.04 -100%

Debt

Parameter Grade Value Sector average Difference with sector, % Average for 5 years Difference from average, %
Debt/Ebitda
9/10
0.9659 0.7755 24.55% 0.6314 +52.97%
Nеt Debt/Ebitda 0 0.0127 -100%
Debt/Ratio 0.0953 0.1229 -22.39%
Debt/Equity 1.77 0.802 120.68%
Debt/Net Income 1.4 1.76 -20.48%

Dividends

Parameter Grade Value Sector average Difference with sector, % Average for 5 years Difference from average, %
Dividend yield
9.78/10
3.91 5.7 -31.4% 1.62 +140.72%
Number of years of dividend growth 3 1.13 166.67%
DSI 1 0.5838 71.29%
Average dividend growth 30.58 3.2 854.84%
Average percentage for 5 years 1.62 4.95 -67.2%
Average percentage for payments 25.01 23.96 4.39%
Difference from average difference in sector -1.79

Growth impulse

Parameter Grade Value Sector average Difference with sector, %
Growth impulse Revenue in 5 years
10/10
163.4 28.69 469.54%
Growth impulse Ebitda in 5 years 145.56 -40.52 -459.23%
Growth impulse Net Income in 5 years 140.59 94.84 48.24%
Growth impulse FCF in 5 years 97.03 91.41 6.15%
Growth impulse EPS in 5 years 11.06 -118.14 -109.36%
IP Score
6.62/10

Similar companies

WuXi Biologics (Cayman) Inc.

Sinopharm Group Co. Ltd.

WuXi AppTec Co., Ltd.

CSPC Pharmaceutical Group Limited

Pay for your subscription

More functionality and data for company and portfolio analysis is available by subscription